RxDoctor Payments Data

Payam Saadat, MD

Dermatology · Burbank, CANPI 1740487925

Payments from drug & device makers

$116,158in general payments, 2019–2025

Across 775 payments — averaging $149.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$70K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$27K
  • Regeneron Healthcare Solutions, Inc.$3K
  • AbbVie$3K
  • Mimedx Group, Inc.$1K
  • Sanofi$1K
  • plus $10K from 33 others

What the payments were for

  • Consulting fees$9,0758%
  • Speaking & faculty fees$79,22568%
  • Travel & lodging$7,4526%
  • Food & beverage$20,30617%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$116,158 in reported general payments places this provider in the 90th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$1,239,977
Medicare patients
1,141
Services billed
6,931

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast22$105,155
SiliqBrodalumab12$62,860
Dupixent PenDupilumab14$53,681
Tacrolimus23$4,981
Fluorouracil49$2,519
Mupirocin437$2,468
Ketoconazole151$1,907
Clobetasol Propionate53$1,489
Metronidazole16$1,441
Triamcinolone Acetonide74$1,090
Clindamycin Phosphate17$826
Fluocinolone Acetonide12$569
Imiquimod22$401
Doxycycline Hyclate29$280
Desonide11$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$314$105,15522 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq$27,498$62,86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,875 dermatology providers in California.

Other dermatology in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →